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Abstract   
Objective 
To estimate the costs and outcomes associated with treating non-asthmatic (nor suffering 
from other lung-disease) adults presenting to primary care with acute lower respiratory tract 
infection (ALRTI) with oral corticosteroids compared with placebo. 
Design 
Cost-consequence analysis alongside a randomised controlled trial. Perspectives included 
the healthcare provider, patients, and productivity losses associated with time off-work. 
Setting 
Fifty-four NHS general practices in England. 
Participants 
398 adults attending NHS primary practices with ALRTI but no asthma or other chronic lung 
disease, followed up for 28 days. 
Interventions 
2x20mg oral prednisolone daily for five days versus matching placebo tablets. 
Outcome measures 
Quality-adjusted life years using the EQ-5D-5L measured weekly; duration and severity of 
symptom. Direct and indirect resources related to the disease and its treatment were also 
collected. Outcomes were measured for the 28-day follow up. 
Results 
198 (50%) patients received the intervention (prednisolone) and 200 (50%) received 
placebo. NHS costs were dominated by primary care contacts, higher with placebo than with 
prednisolone (£13.11 vs £10.38) but without evidence of a difference (95% CI: -£3.05 to 
£8.52). The trial medication cost of £1.96 per patient would have been recouped in 
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prescription charges of £4.30 per patient overall (55% participants would have paid £7.85), 
giving an overall mean ‘profit’ to the NHS of £7.00 (95% CI: £0.50 to £17.08) per patient. 
There was a QALY gain of 0.03 (95% CI: 0.01 to 0.05) equating to half a day of perfect health 
favouring the prednisolone patients; there was no difference in duration of cough or severity 
of symptoms. 
Conclusions 
The use of prednisolone for non-asthmatic adults with ALRTI, provided small gains in quality 
of life and cost savings driven by prescription charges. Considering the results of the 
economic evaluation and possible side effects of corticosteroids, the short-term benefits 
may not outweigh the long term harms. 
 
Strengths and limitations of this study 
 The economic evaluation was part of a rigorously conducted multicentre randomised 
controlled trial, involving a representative population of patients not thought to need 
immediate antibiotic treatment. 
 The economic evaluation included the perspectives of patients and time off work as 
well as the NHS. 
 Low levels of missing cost and outcome data, with EQ-5D observations from multiple 
time points, achieving an accurate profile of patient health-related quality of life over 
the period of the illness. 
 The analysis was thorough and included multiple imputation of missing data and 
extensive sensitivity analysis.   
 
Economic evaluation of the OSAC randomised controlled trial: oral corticosteroids for non-
asthmatic adults with acute lower respiratory tract infection in primary care. 
INTRODUCTION 
Acute lower respiratory tract infection (ALRTI), with symptoms such as wheeze, phlegm, and 
chest pain, is one of the most common reasons for patients to consult in primary care.[1] In 
the UK ALRTI costs the National Health Service at least £190 million annually,[2] and further 
costs are borne by patients in self-managing their condition[3, 4] and by society in general 
because of work absenteeism.[5]  
 
Despite lack of evidence of efficacy and the recommendation from the National Institute for 
Health and Care Excellence of a non-antibiotic pathway,[6] antibiotics are still frequently 
prescribed to treat ALRTI.[7, 8] This unnecessary prescribing fuels antimicrobial resistance, 
raises patient expectations for similar treatment in the future (so-called ‘illness 
medicalisation’), and is a wasteful use of healthcare resources.  
 
Oral and inhaled corticosteroids are widely used to treat symptoms of asthma[9] and there is 
some evidence of the effectiveness of high doses of inhaled corticosteroids in reducing 
cough frequency among non-smokers with ALRTI who do not have asthma or other chronic 
lung disease.[10] Given the similarity in symptoms of ALRTI and those of asthma, we tested 
the hypothesis that corticosteroids might be an effective treatment for ALRTI in adults 
without asthma or other chronic lung disease. Indeed, there is increasing evidence from 
Europe[11] and the United States[12] of steroid prescribing for patients with ALRTI, with a 
secondary analysis of one US study[12] showing 15% of non-asthmatic adults with ALRTI 
being prescribed oral steroids.   
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The OSAC study[13,14] examined the effectiveness and costs of oral corticosteroids (more 
specifically oral prednisolone) in treating ALRTI in a non-asthmatic adult population 
compared with placebo. Here, we report on the results of the economic evaluation. 
 
METHODS 
The OSAC study was a two-arm randomised controlled trial that aimed to test the provision 
of oral corticosteroids to adults with ALRTI but no asthma or other chronic lung disease such 
as chronic obstructive pulmonary disease. Details of the trial procedures and clinical results 
are reported elsewhere.[13,14] Briefly, patients with an ALRTI-related cough were recruited 
from 54 primary care practices across four areas of England and randomly allocated to 
receive either oral prednisolone (intervention) or placebo (control) for their acute cough 
symptoms. The intervention consisted of 40mg (two 20mg tablets) of prednisolone daily for 
five days. The control group received matching placebo tablets. The primary clinical 
outcomes of the study were duration of “moderately bad or worse” cough, and symptom 
severity for days 2 to 4 post randomisation. The primary outcome for the economic 
evaluation was quality adjusted life years (QALYs) which were estimated from responses to 
the EQ-5D-5L.[15] 
 
Design 
The economic evaluation was conducted from the perspectives of the NHS, patients, and a 
broader perspective taking into account differences in work-related productivity costs; we 
included all resource use during the 28-day follow up period. We used a cost-consequences 
design,[16] comparing cost from the three perspectives with the clinical outcomes and 
QALYs, in order to see all possible costs and health consequences.  
 
Identification of resources 
NHS resources were identified as being: the trial medication, primary care consultations, 
other relevant prescribed medication, hospital care, use of NHS 111, and ALRTI-related 
investigations such as chest X-ray. Patient resource use was identified as being: travel, 
prescription costs, and over-the-counter medication and remedies. Productivity losses were 
identified as being days off work due to the cough. 
 
Measurement of resources: data collection 
A primary care notes review took place at the end of the study period and data were 
extracted on: all primary care consultations, categorised as doctor or nurse, face to face, 
telephone or home visit, and in-hours or out-of-hours; prescribed medication; and 
investigations. Participants in the study were issued with a daily diary to complete, which 
was used to collect data on health service use not always reliably available from primary 
care notes such as use of NHS 111 and hospital services. Participant out-of-pocket expenses 
on travel and over-the-counter medicines were also recorded here, along with time off work. 
Participants were telephoned weekly to reinforce their record keeping. 
 
Valuation of resources 
Resources were valued as shown in Table 1. All resources were costed in pounds sterling at 
2013-2014 prices, using an appropriate inflation index[17] when necessary. Costs for primary 
care services were obtained from Curtis;[17] calls to the NHS 111 service were costed using a 
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published national evaluation[18] and NHS reference costs[19] were used to value secondary 
care services. Travelling by car was valued using the AA running schedule to cost the 
mileage,[20] and standard ticket prices were employed to cost the use of public transport. 
Productivity costs were derived using the age/sex average rate from the Annual Survey of 
Hours and Earnings.[21]  
 
For prescribed medication, costs were extracted mainly from the British National Formulary 
(BNF).[22] A cost was obtained for each prescription based on the name of the drug, the 
method of administration (for example, tablet, capsule, liquid) and the number of units 
included in the prescription. When the cost of a drug was not available in the BNF, the 
Prescription Costs Analysis of England database[23] was used to cost that medication. 
Uncertainties around relevance (to ALRTI) and missing information were resolved by seeking 
clinical advice. 
 
Careful consideration was given to the most accurate way of costing the intervention 
medication (prednisolone) with the aim of reflecting the true cost to the NHS if it were to be 
adopted as a strategy for treating ALRTI. First, thought was given to the number of pills that 
would be needed to cover the intervention total dose as the 20mg tablets provided in the 
study are not routinely available. We assumed that 5mg tablets would be a reasonable 
substitute, resulting in 8 tablets required per day, and 40 tablets for the duration of the 
intervention (5 days). From the basic price of £1.03 given in the BNF, adjustments were 
made as follows. We subtracted the usual discount (7.61% of the basic price) eligible to the 
dispensing pharmacy from the manufacturer; we added a standard 90p dispensing fee and a 
payment of 1.24p for consumables; and as the amount required was 40 and packs contain 28 
tablets, an extra 10p for splitting packs was added. This resulted in a cost for the intervention 
prednisolone of £1.96. To reflect a ‘roll-out’ situation, we allowed for potential receipts from 
prescription payments made by patients by including an amount for those participants who 
reported that they usually pay a prescription charge.   
No cost was included for the placebo medication (i.e. tablets) as this was a research cost. 
 
Measurement and valuation of outcomes 
The EQ-5D-5L was completed weekly by participants from baseline during the 28-day follow 
up, giving us five observations to use to form QALYs. Utilities were obtained from existing 
preferences elicited from the general public, using the crosswalk algorithm.[15] QALYs were 
calculated from these utilities using the area under the curve and adjusting for baseline 
differences.[24]  
Results from the clinical trial [14] show that the median duration of moderately bad or worse 
cough was 5 days in both groups and the hazard ratio of 1.11 (95% CI: 0.89 to 1.39) also 
indicates no difference. There was a reduction of 0.02 in mean symptom score for days 2 to 4 
in prednisolone patients though this was less than the pre-determined clinically meaningful 
difference.    
 
Data analysis 
Frequencies of resource use were calculated to provide a descriptive analysis of the types of 
resources used by primary care patients with a cough. We estimated mean resource use and 
cost per patient for all categories, by trial arm, to compare the prednisolone group with 
those using the placebo. Ordinary least squares regressions were employed to calculate the 
differences in costs adjusted for centre, age, gender and outcome-related baseline variables, 
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in order to account for potential imbalances between the groups. Standard deviations (for 
means) and bias-corrected bootstrapped confidence intervals[25] (2,000 replicates) were 
constructed to account for the uncertainty in the point estimates.  
 
No discount was applied to the data as the time horizon of the study was 28 days. All 
analyses were carried out using Stata 13 and above.[26] 
 
Sensitivity Analyses 
Five different sensitivity analyses were conducted to test the robustness of assumptions 
made in the base case analysis. The effect of missing data was appraised in two scenarios 
using multiple imputation techniques: in addition to the imputation with chained equations 
(ICE) (scenario 1), which is usually employed in economic evaluations, an analysis was also 
carried out using the ‘twofold’ command in Stata; this command imputes missing values at a 
given time point, conditional on information at the same time point and immediately 
adjacent time points [27] (scenario 2), to be consistent with the methodology used in the 
clinical effectiveness analysis.[14] Scenario 3 excluded outpatient and A&E attendances 
where there was any ambiguity about their relevance to LRTI; scenario 4 used the visual 
analogue scale to calculate QALYs; and scenario 5 removed the prescription payments from 
the analysis on the basis that these are to some extent artefactual and relate specifically to 
England at the time of the study.  
 
Patient and public involvement 
Patient participation and involvement (PPI) input was important in the decision to prioritise the 
research question for funding, and their views informed discussions around the design of the study, 
the sample size calculation and selection of primary and secondary outcomes. PPI views were sought 
on recruitment methods, and all patient facing trial materials. The burden of the intervention was 
also assessed by patients themselves and results were disseminated to both practices and the 
patients. We wish to thank our PPI advisors for their input into trial design and management. 
 
RESULTS 
In total, 398 patients were included in the intention-to-treat analysis. One hundred and 
ninety eight (49.7%) were in the trial medication (intervention) group and 200 (50.3%) 
received the matched placebo (control). Baseline characteristics of the participants are 
shown in Table A of the appendix. Participants were predominantly white, employed, and 
middle-aged and similar rates received asthma medication in both groups (5% vs. 4%) during 
the previous years. Approximately 50% in both arms stated they had never smoked. Data on 
NHS costs were complete for 332 (83%) participants and out-of-pocket costs for patients 
were reported by 329 (83%). Time off work was recorded by 321 (81%) of the participants 
filling the questionnaire and 346 (87%) completed the EQ-5D-5L at all five time points.   
 
Resource use 
Use of all health services was relatively modest during the 28 day follow up period. Overall 
just 20% participants accessed primary care, a proportion that was similar for both groups 
though patients in the placebo group had slightly more consultations per patient than those 
in the prednisolone group, which is reflected in the mean number of encounters (0.30 vs 
0.27) as shown in Table 2. Prescribed medication was also slightly higher in the placebo 
group in terms of number of patients (15% vs 12%) being prescribed anything and the mean 
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number of prescriptions per participant (0.22 vs 0.15). Nine participants (2%) reported using 
hospital services: three (1.5%) in the prednisolone group and six (3%) in the placebo group.     
 
More placebo group participants reported buying over-the-counter medications than those 
in the prednisolone group (45% vs 39%) and the mean number of items per participant was 
higher (0.59 vs 0.48). Popular items included cough linctus and cold & flu remedies. Similarly, 
more placebo group participants reported time off work than prednisolone participants 
(32% vs 28%) and the mean length of time off was longer (1.38 days vs 0.95 days).  
 
Although there was a consistently higher use of resources in the placebo group compared 
with the prednisolone group there is imprecision around the point estimates and, with the 
exception of the trial medication and associated prescription payments, there is no evidence 
of a difference in use between the groups as indicated by the confidence intervals reported 
in Table 2.  
 
Cost analysis 
Table 3 summarises the cost comparison between the two groups. The majority of NHS costs 
were attributable to primary care consultations with hospital visits, including for X-rays, 
contributing a modest amount. Over half (55%) of prednisolone participants reported that 
they normally pay a prescription charge; the value of prescription payments made by these 
patients more than covered the cost of the trial medication meaning that the NHS on 
balance would have made a profit. Out-of-pocket patient costs were dominated by 
prescription payments and the value of time off work was higher than any other category of 
cost. Comparing the prednisolone and placebo groups, costs were higher in the placebo 
group for all categories (except those related to the trial medication) though again there was 
no evidence of a difference between the groups as indicated by the confidence intervals. 
 
Cost-consequence analysis 
Table 4 shows the comparison of incremental costs and outcomes, including the results from 
the clinical trial regarding duration of cough and symptom severity score. Here we present 
the difference in cost by perspective, adjusted by centre, age, gender, and baseline 
covariates. The 95% confidence intervals are bootstrapped and bias corrected. The negative 
incremental cost of -£7.00 (95% CI: -£17.08 to -£0.50) per patient to the NHS indicates the 
intervention is cheaper than placebo; it reflects the lower use of primary care by patients in 
the prednisolone group and the offset of intervention costs by prescription payments. From 
the patient perspective, despite higher travel and over the counter costs in the placebo 
group, total costs were approximately £3 more in the prednisolone group due to the cost of 
prescriptions. The value of time off work was approximately £30 higher per patient for the 
placebo group.  
 
The gain in quality of life provided by the prednisolone was 0.03 QALYs (95% CI: 0.01 to 0.05) 
per patient, which translates into slightly more than half a day of extra ‘best imaginable’ 
health during the 28 days. The percentage of patients reporting no problems for each 
domain of the EQ-5D are shown in table B of the Appendix. On average, the prednisolone 
patients improved by more than the placebo patients in all domains but the ‘pain and 
discomfort’ and ‘usual activities’ domains were where the greatest difference was seen.  
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Sensitivity analysis 
Results of the sensitivity analyses are presented in Table 5. Imputing missing data, and 
excluding unrelated costs make no difference to the conclusions of the base case analysis. 
Using the visual analogue scale (VAS) to value the QALYs reduced the QALY gain of 
prednisolone patients over placebo to a minimal amount (0.01: 95% CI: -0.01 to 0.03). When 
prescription payments are removed the incremental cost to the NHS is still negative (-£3.04; 
95% CI: -£11.31 to £5.24) though the confidence interval suggests no evidence of a true 
difference. The reverse is true for patient costs as placebo patients spent considerable more 
on travel and over-the-counter medications and remedies than those in the prednisolone 
group.      
 
DISCUSSION 
Summary of main findings 
Prednisolone was found to be clinically ineffective for treating ALRTI in non-asthmatic adults 
in primary care in terms of duration of cough and symptom severity [14]; however there was 
evidence that patients using prednisolone experienced a greater improvement in health-
related quality of life than those using the placebo. This was largely due to a greater 
improvement in pain/discomfort and a speedier return to carrying out usual activities. 
Prednisolone is a relatively inexpensive medication and, in this population of generally 
healthy adults ineligible for prescription charge exemption, prescription payments more 
than offset the cost to the NHS. Other NHS resource use was consistently higher in the 
placebo group across all categories though the differences were small. The value of time off 
work was considerable and this was higher in the placebo patients, though the limited 
sample size combined with patient-level variation prevented a robust conclusion.  
 Strengths and weaknesses 
The sample included in OSAC was typical of patients consulting in primary care with ALRTI, 
not thought to require immediate antibiotic treatment. The two groups were well matched 
at baseline and there was minimal drop-out. The economic evaluation was carried out at 
individual patient level and covered the whole 28 day period. Data on actual utility values for 
each group was not reported, which would have helped to understand the differences 
regarding quality of life data between each group; however, the weekly collection of EQ-5D-
5L data allowed for an accurate estimate of the recovery profile of patients, capturing the 
speedier improvement of those in the prednisolone group, suggesting that they ‘felt better’ 
more quickly than those taking the placebo. In this trial there were low levels of missing 
data, however when estimating cost at a number of time points over the whole trial period 
any missing resource use data pose a threat. From the NHS perspective, there were 332 
complete cases representing 83% of the total sample who provided data at all time points. 
The total amount of missing data points was less than this which is borne out by the results 
of the multiple imputation, confirming that the complete cases estimates are robust. The 
size of the sample for the trial was based on the primary clinical outcomes, as is common 
practice. Patient variability affected the uncertainty around the estimates of mean cost, so 
although there were suggestions of differences between the groups (especially for time off 
work), the sample was not large enough for this to be confirmed beyond chance. The 
economic evaluation was restricted by the procedures and time frame of the trial. We did 
not include a cost for the placebo medication but it is possible that in a ‘real life’ situation an 
alternative treatment such as a codeine linctus, an inhaler, or an oral antibiotic might be 
prescribed. Although it was appropriate to limit the follow up period to 28 days to answer 
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the clinical question we were unable to capture any long term effects of either repeated use 
of corticosteroids, such as illness medicalisation or osteoporosis,[28] or a reduction in 
repeated days off work.  
 
Comparison with other literature (strengths and weaknesses) 
We are aware of no other studies investigating the clinical and economic implications of 
corticosteroids for ALRTI. However, our estimates of cost and quality of life can be compared 
separately with other literature. Oppong et al.[29] conducted a thorough analysis of 
resource use and cost for acute cough/LRTI in 13 European countries. The use of primary 
healthcare services in that study was slightly higher than our figure of 0.28 per participant: 
they found a mean of 0.34 visits for the two UK centres included in the study, and an overall 
range of 0.30 to 1.89. However this difference is small and may be accounted for by different 
inclusion criteria. On the other hand, the amount of time off work was considerably 
different. Our participants reported a mean length of 1.16 days off work compared to 3.08 in 
the European study, though it is difficult to tell whether those authors included a value 
(representing ‘potential’ time off) for participants not in paid work. Only one third of our 
participants reported any time off work but for those who did, the mean length was 3.9 
days. In this study we found a small but significant improvement in quality of life for patients 
taking prednisolone compared with those taking the placebo. In a recent review of short 
course oral steroids for chronic rhinosinusitis[30] an improvement in quality of life was 
observed at the end of a two to three week course though the quality of this evidence was 
judged to be low. There is also some evidence of patients reporting positive mood change 
when taking steroids.[31]  
 
Meaning of the study/Policy implications 
The results of this study pose an interesting challenge in terms of interpretation. Despite the 
negative clinical (cough duration and symptom severity) endpoint results, we found 
prednisolone was cheaper (in terms of NHS costs) than placebo and better (in terms of QALY 
gain), but each of these findings comes with a caveat. Once the benefit of prescription 
payments was removed from the analysis the cost gain was much reduced, and could have 
been due to chance. Placebo patients consistently used more healthcare services than those 
on prednisolone but as the trial was not powered to detect a difference in cost, we cannot 
draw any firm conclusions. Although the short term use of prednisolone may make patients 
feel a little better, the negative effects of longer term or repeated use, such as illness 
medicalisation[32] and osteoporosis[28] cannot be accounted for in this analysis and are 
potentially powerful arguments against more widespread use. 
The results of this study evidence a small increment of the quality of life - particularly in 
pain/discomfort and resumption of usual activities -in patients who take prednisolone to 
treat their ALRTI symptoms. However, taking the clinical and economic implications derived 
from this study, and considering the possibility of side-effects from repeated short-term use, 
the benefits may not outweigh the unknown long term risk. 
 
Unanswered questions and future research 
This study has addressed the question of the short term use of corticosteroids for ALRTI but 
more work is needed to understand the longer term influences. One motivation for carrying 
out the research was concern about inappropriate prescribing of antibiotics for conditions 
such as ALRTI, particularly with respect to the effect on antimicrobial resistance. 
Corticosteroids are successfully used in the short term for many conditions and the long 
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term detrimental effects, such as osteoporosis, high blood pressure, and suppression of the 
immune system are recognised; a recent study [33] showed that adverse events can develop 
within one month of short-term steroid use in patients with acute respiratory tract 
infections; however, the specific long term effect of repeated short term use of steroids by 
ALRTI patients is uncertain. Future work could include long term modelling of the costs and 
effects of alternative treatments for ALRTI, including corticosteroids, antibiotics, and other 
medications with little or marginal effect such as linctus. The modelling could take a broad 
perspective, including the impact of lost productivity, and address the challenge of weighing 
up the societal cost of antimicrobial resistance against patient level side-effects of 
medication and the potential for over-medicalisation of ALRTI. In some studies[34,35], the 
small gains in time to recovery provided by antibiotics (12 to 24 hours) was not sufficient to 
outweigh their risks. Our study did not measure this variable; however, future research 
would be necessary to ascertain whether a similar conclusion could be obtained for 
prednisolone. 
 
Conclusion 
The economic evaluation evidences gains in quality of life provided by the use of 
prednisolone for non-asthmatic adults with ALRTI from the perspective of the NHS. However, 
the benefit is small and taking the clinical and economic implications derived from this study, 
and considering the potential side effects from repeated use of corticosteroids, the short-
term benefits may not outweigh the long term harms. 
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Table 1. Valuation of resource use 
 
Category of Resource Unit Cost 2013/14 
Primary Care Services 
GP (face to face in practice) 46.00a 
GP (telephone call) 28.00 a 
GP (out of hours) 68.30 a 
Practice nurse (face to face in practice) 13.69 a 
Practice nurse (telephone call) 9.00 a 
Nurse practitioner(face to face in practice) 25.00 a 
Nurse practitioner (out of hours) 33.41 a 
NHS 111 calls 8.29b 
Hospital and Walk-in Services 
Walk-in centre 40.50c 
Outpatient 150.00/214.00d* 
A&E visits 111.20 c 
Investigations (X-ray) 28.01 c 
Medication 
Prescribed medication By itemd,e 
Prednisolone (intervention) 1.96d,e 
Over the counter medication By item 
Prescription charge 7.85 
Other 
Mileage 0.64f 
Time off work 118.24g 
a Curtis [17] 
b Evaluation report [18] 
c NHS reference costs [19] 
d BNF [22] 
e Prescription Pricing Authority [23] 
f AA schedule [20] 
g Office of National Statistics [21] 
 
*£214.00 was used for a patient who had a very resource-intensive outpatient stay (upper bound outpatient cost) 
 
 Table 2. Mean (SD) resource use, per patient, by category and group (all available data) 
 Prednisolone Placebo Unadjusted difference 
Resource use category n Mean (SD) n Mean (SD) Mean (95% CI) 
Primary care consultations 195 0.27 (0.58) 198 0.30 (0.73) -0.03 (-0.16 to 0.10) 
Prescribed medication 190 0.15 (0.51) 200 0.22 (0.64) -0.06 (-0.18 to 0.05) 
NHS 111 calls 177 0.04 (0.22) 168 0.02 (0.13) 0.02 (-0.02 to 0.06) 
X-ray procedures 197 0.04 (0.19) 198 0.04 (0.20) 0.00 (-0.04 to 0.03) 
All hospital visits  176 0.02 (0.13) 166 0.04 (0.23) -0.03 (-0.06 to 0.01) 
Trial medication 198 1 (0) 200 0 (0) 1 (1 to 1) 
Prescription payments 191 0.62 (0.66) 181 0.09 (0.39) 0.52 (0.41 to 0.64) 
Over the counter medication 180 0.48 (0.67) 168 0.59 (0.83) -0.11 (-0.26 to 0.05) 
Time off work (days) 171 0.95 (2.61) 165 1.38 (3.05) -0.43 (-1.04 to 0.18) 
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Table 3. Mean (SD) cost (£) by group, per patient, by category and group (all available 
data) 
 
 
Prednisolone Placebo Unadjusted 
difference 
Resource use category n Mean (SD) n Mean (SD) Mean (95%CI) 
Primary care consultations 195 10.38 (23.97) 198 13.11 (33.52) -2.73 (-8.52 to 3.05) 
Prescribed medication 195 0.36 (1.27) 194 0.44 (1.33) -0.08 (-0.34 to 0.17) 
NHS 111 calls 168 0.33 (1.85) 177 0.33 (1.85) 0.18 (-0.14 to 0.50) 
X-ray procedures 198 1.00 (5.20) 197 1.00 (5.20) -0.14 (-1.20 to 0.93) 
All hospital visits  176 1.09 (9.39) 166 3.84 (23.10) -2.75 (-6.46 to 0.97) 
Trial medication 198 1.96 (0) 200 0 (0) 1.96 (1.96 to 1.96) 
Prescription paymentsa 191 4.85 (5.20) 181 0.74 (3.06) 4.11 (3.24 to 4.99) 
Over the counter medication 175 2.23 (3.93) 165 3.08 (5.07) -0.85 (-1.82 to 0.11) 
Travel costs 171 1.76 (2.63) 166 2.45 (4.39) -0.69 (-1.47 to 0.08) 
Time off work (days) 
161 58.02 (161.16) 160 
83.88 (183.93) 
-25.86 (-63.83 to 
12.11) 
 
a Prescription payments are a transfer cost between the NHS and patients. They are a negative cost 
(receipt) to the NHS and a positive cost to patients 
 
 
 
 
 
Table 4. Cost-consequence analysis. Differences in mean (95%CI) cost and Quality Adjusted 
Life Years (complete cases, by perspective) 
 Mean (95% CI)a Difference 
All NHS services (n=332) -£7.00 (-£17.08 to -£0.50) 
All patient out-of-pocket expenditure (n=329) £2.90 (£1.14 to £4.48) 
Value of time off work (n=321) -£30.45 (-£ 67.15 to £9.79) 
  
QALYs (n=346) 0.03 (0.01, 0.05) 
Duration of cough (n=334) Hazard Ratio: 1.11 (0.89 to 1.39) 
Symptom severity score (n=368) -0.20 (-0.40 to 0.00) 
 
a biased corrected and adjusted by centre  and baseline covariates 
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Table 5. Sensitivity Analyses: incremental costs and QALYs under different scenarios. 
SCENARIO 
Differences in 
means* 
(95% CI) 
1. Imputed data (ICE)  
NHS services -£9.78 (-£19.05 to -£3.87) 
Patient out-of-pocket expenditure £3.01 (£1.06 to £4.28) 
Value of time off work -£22.99 (-£55.81 to £12.97) 
QALYs 0.03 (0.01 to 0.04) 
2. Imputed data (TWOFOLD)  
NHS services -£7.27 (-£17.12 to -£0.91) 
Patient out-of-pocket expenditure £2.97 (£1.16 to £4.54) 
Value of time off work -£28.36 (-£67.75 to £9.38) 
QALYs 0.03 (0.01 to 0.04) 
3. Exclusion of potentially unrelated cost categories 
(n=332) 
 
NHS services -£6.20 (-£13.77 to £0.14) 
4. QALYs using VAS (n=326)  
QALYs 0.01 (-0.01 to 0.03) 
5. Removal of prescription payments (n=334)  
NHS services -£3.04 (-£11.31 to £5.24) 
Patient out-of-pocket expenditure -£1.49 (-£2.83 to -£0.16) 
 
*adjusted by centre and baseline covariates 
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Appendix 
Table A. Participants’ baseline characteristics 
 Prednisolone 
(N=198) 
Placebo 
(N=200) 
Centre, n (%)   
Bristol 118 (60%) 113 (57%) 
Oxford 39 (20%) 45 (23%) 
Southampton 24 (12%) 21 (11%) 
Nottingham 17 (9%) 21 (11%) 
Demographics and past medical history 
Gender, n (%) male 82 (41%) 66 (33%) 
Age, mean (SD) 50.0 (16.1) 44.8 (15.5) 
Weight kg, median (IQR)a 77.0 (64.5,91.0) 76.0 (66.5,90.5) 
Height cm, median (IQR)b 168.0 
(161.0,175.0) 
168.0 (163.0,176.0) 
Ethnicity, n (%) whitec 188 (95%) 193 (97%) 
Occupation, n (%)   
Employed 137 (69%) 143 (72%) 
Unemployed 17 (9%) 21 (11%) 
Retired 41 (21%) 30 (15%) 
Full-time education 3 (2%) 6 (3%) 
Deprivation (IMD)d, median (IQR)e 11.0 (5.0,23.0) 12.0 (5.0,23.0) 
Smoking status, n (%)f   
Current  31 (16%) 38 (19%) 
Past  63 (32%) 55 (28%) 
Never 104 (53%) 106 (53%) 
Lives with smoker, n (%)g 25 (14%) 32 (16%) 
Received asthma medication >5 years previouslyh 10 (5%) 8 (4%) 
Personal history of hay feveri 41 (22%) 46 (24%) 
Personal history of eczemaj 30 (16%) 26 (14%) 
Family history asthma/hay fever/eczema, n (%)k 73 (40%) 76 (40%) 
Influenza vaccine in last 12 months, n (%) 63 (32%) 44 (22%) 
Recruited in winter (1st Oct-31st March) 112 (57%) 114 (57%) 
Clinical characteristics and management 
Prior duration of cough, median (IQR) days 13.0 (7.0,20.0) 10.0 (6.0,17.5) 
Sputum (symptom <24hr), n (%)l 149 (76%) 156 (78%) 
Shortness of breath (symptom <24hr) n (%) 146 (74%) 133 (67%) 
(Table continues on next page) 
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Table A. Participants’ baseline characteristics (cont.) 
 Prednisolone 
(N=198) 
Placebo 
(N=200) 
Wheeze (symptom <24hr), n (%)l 88 (45%) 98 (49%) 
Chest pain (symptom <24hr) n (%) 88 (44%) 97 (49%) 
Patient reported illness severity (0-10), median 
(IQR)m 
6.0 (5.0,7.0) 5.0 (4.0,7.0) 
Pulse rate (bpm), mean (SD) 77.8 (12.3) 77.7 (11.8) 
Temperature (⁰C), mean (SD) 36.6 (0.5) 36.6 (0.4) 
Oxygen saturation (%), mean (SD)n 97.5 (1.3) 97.8 (1.1) 
Baseline abnormal peak flowo 87 (44%) 79 (40%) 
Abnormal respiratory rate, n (%) 2 (1%) 1 (1%) 
Chest recession/prolonged expiration  0 (0%) 1 (1%) 
Wheeze/rhonchi (auscultation), n (%)  11 (6%) 11 (6%) 
Crackles/crepitations (auscultation), n (%)p 4 (2%) 6 (3%) 
Bronchial breathing  0 (0%) 2 (1%) 
Taken prescribed β agonist in past 24 hours, n (%) 9 (5%) 3 (2%) 
OTCq drugs taken for current cough, n (%) 128 (65%) 139 (70%) 
Given delayed antibiotic script, n (%) 22 (11%) 25 (13%) 
 
 
a Weight missing for 2 prednisolone participants 
b Height missing for 1 prednisolone participant 
c Ethnicity missing for 1 placebo participant 
d English Index of Multiple Deprivation scores (2015) [Geoconvert: UK Data Service Census Support] 
e IMD missing for 2 prednisolone and 7 placebo participants  
f Smoking status missing for 1 placebo participant 
g Living with smoker missing for 15 prednisolone and 5 placebo participants 
h Personal history of asthma missing for 10 prednisolone patients and 7 placebo patients 
I Personal history of hayfever missing for 10 prednisolone patients and 11 placebo patients 
j Personal history of eczema missing for 14 prednisolone patients and 10 placebo patients 
k Family history of hay fever/eczema/asthma missing for 16 prednisolone and 11 placebo participants  
l Sputum and wheeze presence in 24 hours, missing for 1 prednisolone participant 
m Patient reported illness severity measured on zero to 10 scale, missing for 1 prednisolone participant 
n Oxygen saturation missing for 1 prednisolone participant 
o Baseline abnormal peak flow (defined as <80% of expected peak flow) was missing for 1 prednisolone patient 
p Includes unilateral and bilateral  
q Over-the-counter 
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Table B. Percentage of patients reporting no problems in response to the five domains of 
the EQ-5D 
 
  
Baseline – all 
participants 
(n=199 placebo; 
198 prednisolone) 
Baseline – 
participants with 
week 4 data 
(n=171 placebo; 177 
prednisolone) 
Week 4 
(n=171 placebo; 
177 prednisolone) 
Mobility Placebo 93.0 94.1 94.7 
 Prednisolone 91.9 91.5 94.4 
Self-care Placebo 97.5 97.7 97.1 
 Prednisolone 99.0 98.9 99.4 
Usual activities Placebo 89.9 90.0 83.0 
 Prednisolone 82.3 82.5 93.2 
Pain/discomfort Placebo 61.3 62.9 81.3 
 Prednisolone 55.6 54.8 87.6 
Anxiety/depression Placebo 83.4 84.1 86.5 
 Prednisolone 82.3 82.5 89.3 
 
 
 
